Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAXON-PC
NCT05133440Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2021
- Primary completion
- Apr 2026
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2021; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05133440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133440.